Five things for pharma marketers to know: Friday, August 24, 2018
White House proposes rule for drug prices in DTC ads; FDA to study impact of side-effects warnings in drug ads; FDA approves Shire’s potential blockbuster HAE treatment.
Drug Pricing
Pfizer reorg came on heels of its walk-back on price hikes
Wednesday’s reorg was designed to position the company for growth in the face of the imminent patent cliff for megablockbuster Lyrica.
Three quarters of Americans support listing drug prices in DTC ads: Kaiser survey
Across the political spectrum, most Americans favor President Donald Trump’s proposal to show drug prices in advertisements.
